Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00561418 | Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma | completed | Phase 1 | 23 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 16, 2015 | clinicaltrials |
| NCT01403415 | Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma | completed | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 2 | Jul 10, 2015 |
| clinicaltrials |
| NCT00413075 | Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 121 | Valerio TherapeuticsINDUSTRY | 3 | Jul 8, 2015 | clinicaltrials |
| NCT00608361 | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 80 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2015 | clinicaltrials |
| NCT00324220 | A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 66 | Mirati Therapeutics Inc.INDUSTRY | 1 | Jul 1, 2015 | clinicaltrials |
| NCT00689507 | A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib | completed | Phase 1 | 48 | Applied Molecular EvolutionINDUSTRY | 1 | Jun 29, 2015 | clinicaltrials |
| NCT01217749 | Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL(PCYC-1109-CA) | completed | Phase 1 / Phase 2 | 71 | Pharmacyclics LLC.INDUSTRY | 1 | Jun 25, 2015 | clinicaltrials |
| NCT00175812 | Differentiation Induction in Acute Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 24 | University of BergenOTHER | 1 | Jun 24, 2015 | clinicaltrials |
| NCT00995332 | Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine | completed | Phase 1 / Phase 2 | 36 | University of BergenOTHER | 1 | Jun 24, 2015 | clinicaltrials |
| NCT01126814 | A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 35 | University Health Network, TorontoOTHER | 1 | Jun 24, 2015 | clinicaltrials |
| NCT02480608 | Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004)(CML2004) | completed | Phase 1 / Phase 2 | 113 | University of LeipzigOTHER | 0 | Jun 24, 2015 | clinicaltrials |
| NCT00990587 | Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy | completed | Phase 1 | 20 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT01531998 | Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 19, 2015 | clinicaltrials |
| NCT00947739 | Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma | completed | Phase 1 | 43 | New Mexico Cancer Research AllianceOTHER | 1 | Jun 18, 2015 | clinicaltrials |
| NCT00034684 | Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701) | completed | Phase 1 / Phase 2 | 132 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 17, 2015 | clinicaltrials |
| NCT00720135 | Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | completed | Phase 1 | 9 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01041443 | 5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01344876 | Phase I Study of OPB-51602 in Patients With Hematologic Malignancies | completed | Phase 1 | 20 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01602289 | A Study of LY2875358 in Japanese Participants With Advanced Cancer | completed | Phase 1 | 17 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 8, 2015 | clinicaltrials |
| NCT00453427 | Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas(ACCAPELA) | completed | Phase 1 / Phase 2 | 20 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Jun 3, 2015 | clinicaltrials |
| NCT00111813 | Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1)) | completed | Phase 1 | 34 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 21, 2015 | clinicaltrials |
| NCT01795716 | Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body | completed | Phase 1 | 21 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 19, 2015 | clinicaltrials |
| NCT00493571 | Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes | completed | Phase 1 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | May 13, 2015 | clinicaltrials |
| NCT00778752 | Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma | completed | Phase 1 / Phase 2 | 24 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 13, 2015 | clinicaltrials |
| NCT00402558 | Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | completed | Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | May 8, 2015 | clinicaltrials |
| NCT01149915 | Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias | completed | Phase 1 | 40 | Threshold PharmaceuticalsINDUSTRY | 1 | May 7, 2015 | clinicaltrials |
| NCT01551524 | Phase I Study of mPEG-R-Crisantaspase Given IV | completed | Phase 1 | 36 | Jazz PharmaceuticalsINDUSTRY | 1 | May 7, 2015 | clinicaltrials |
| NCT01220648 | Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)(NICOLI) | completed | Phase 1 | 4 | Novartis PharmaceuticalsINDUSTRY | 1 | May 5, 2015 | clinicaltrials |
| NCT00007956 | Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00020462 | Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00045500 | UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00085150 | LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00923182 | A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | completed | Phase 1 | 6 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00991133 | A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL) | completed | Phase 1 | 8 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00002765 | Immunotoxin in Treating Patients With Leukemia or Lymphoma | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00003993 | Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 24 | National Institute on Aging (NIA)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00019318 | Depsipeptide in Treating Patients With Solid Tumors | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00019344 | Flavopiridol in Treating Patients With Refractory Cancer | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00019656 | Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00019838 | UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00020111 | Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 3 | Apr 29, 2015 | clinicaltrials |
| NCT00021983 | Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00019032 | Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia | completed | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2015 | clinicaltrials |
| NCT00217646 | Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2015 | clinicaltrials |
| NCT00506922 | Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT | completed | Phase 1 / Phase 2 | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 28, 2015 | clinicaltrials |
| NCT01390311 | Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant | completed | Phase 1 | 14 | Washington University School of MedicineOTHER | 1 | Apr 27, 2015 | clinicaltrials |
| NCT00771472 | Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1) | completed | Phase 1 | 10 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 21, 2015 | clinicaltrials |
| NCT00871663 | Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6) | completed | Phase 1 | 123 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 20, 2015 | clinicaltrials |
| NCT00383474 | Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT01332786 | Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia | completed | Phase 1 | 27 | University Health Network, TorontoOTHER | 2 | Apr 15, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Jul 16, 2015source: clinicaltrials